| Literature DB >> 30302010 |
Kishin Koh1, Yuta Ichinose1, Hiroyuki Ishiura2, Haitian Nan1, Jun Mitsui3, Junya Takahashi4, Wakiro Sato5, Yoshiaki Itoh6, Kyoko Hoshino7, Shoji Tsuji3,8, Yoshihisa Takiyama9.
Abstract
PLA2G6-associated neurodegeneration (PLAN) comprises heterogeneous neurodegenerative disorders, including infantile neuroaxonal dystrophy, neurodegeneration with brain iron accumulation 2B, and Parkinson disease 14 (PARK14). In addition, very recently, PLA2G6 mutations have been reported to represent a phenotype of hereditary spastic paraplegia (HSP). In this study, we screened 383 HSP families to clarify the frequency of PLA2G6 mutations in the Japan Spastic Paraplegia Research Consortium, and revealed the clinical characteristics of HSP with PLA2G6 mutations. We found three families with compound heterozygous mutations of the PLA2G6 gene, c.517 C > T/c.1634A > G, c.662 T > C/c.991 G > T, and c.1187-2 A > G/c.1933C > T, and one family with a homozygous mutation of the PLA2G6 gene, c.1904G > A/c.1904G > A. All three families with compound heterozygous mutations presented a uniform phenotype of a complicated form of HSP with infantile/child-onset spastic paraplegia, cerebellar ataxia, and mental retardation. On the other hand, the family with a homozygous mutation presented a late-onset complicated form of HSP with parkinsonism. This study may extend the clinical and genetic findings for PLAN.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30302010 DOI: 10.1038/s10038-018-0519-7
Source DB: PubMed Journal: J Hum Genet ISSN: 1434-5161 Impact factor: 3.172